CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S267
DOI: 10.1055/s-0039-1686043
Poster
Oncology

Retrospective case series on patients with head and neck cancer and haematooncological diseases

A Pfaue
1   Universitätsklinikum Ulm, Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Ulm
,
J Krönke
2   Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm
,
J Greve
1   Universitätsklinikum Ulm, Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Ulm
,
TK Hoffmann
1   Universitätsklinikum Ulm, Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Ulm
,
P Schuler
1   Universitätsklinikum Ulm, Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Ulm
› Author Affiliations
 

Introduction:

Haematooncological diseases and their therapy can trigger permanent immunosuppression and thus encourage the development of further neoplasia. The weakened immune system can also influence the prognosis of secondary neoplasia in the head and neck area.

Methods:

Retrospective case series on patients with head and neck cancer following the onset of haematooncological disease (n = 15). Investigation of tumor stage, previous therapy and course of disease.

Results:

The mean age at time of initial diagnosis was 51 years for the haematooncological disease and 62 years for the head and neck cancer. The mean duration between initial diagnosis of the haematooncological disease and the head and neck cancer was 137 +/- 111 months. All patients received immunosuppressive radio-, chemo- and/or immunotherapy for the haematooncological disease. Secondary malignancies in the head and neck area showed a recurrence or progression under therapy in 67% despite standard therapy, in 53% within the first year. In three cases, a third carcinoma occurred in the head and neck area. In four cases, patients developed another malignant tumor outside the head and neck area. In two patients, an additional risk factor was immunosuppressive therapy due to a preexisting autoimmune disease.

Conclusion:

Patients with head and neck cancer after haematooncological diseases show markedly unfavorable courses of disease with tumor progression under therapy, increased risk of recurrence and secondary malignancies. Therefore, a close tumor follow-up is of major importance. Adjuvant immune-enhancing measures may have a positive impact on the course of disease.



Publication History

Publication Date:
23 April 2019 (online)

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York